With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.10534-59-5,Tetrabutylammonium acetate,as a common compound, the synthetic route is as follows.
To a 3-litre three necked round bottomed flask flushed with dry nitrogen the O- benzyl-chlorolactol methyl acetal (30g) was charged into dry N-methyl pyrollidinone (756mis). Anhydrous tetrabutylammonium acetate (102.57g) was also charged to the solution. The reaction mixture was then heated at 100C for 24 hours. The reaction mixture was sampled at routine intervals and directly analysed by tlc and gc/ms. The black solution was then diluted with water (150mis) and extracted with ethyl acetate (3 x 1500mis). The combined upper organic layer was then washed with water (3 x 1500mls). The aqueous portion showed no product content at this point. The layers were then separated, dried, (Na2SO4) and the solvent removed in vacuo to yield a black flowing oil (31g, 95%) containing a mixture of anomers.’H nmr CDCI31. 4-1.8 (m 4H), 2.0- 2.1 (duplicate s, 3H), 3.4 & 3.5 (s 3H), 3.8 (m 1H), 4.0 (m 1H), 4.1 (m 2H), 4.5 (m, 2H), 4.7-4. 9 (m 1H), 7.2-7. 3 (m, 5H) ; 13C nmr CDCI3 20.8 ; 30-35; 55&56; 57&64; 66&68; 69&72; 70&71; 98&99; 127-128 & 138; 170.5 ; m/z 293,262, 221,203, 156,91 and 43.
10534-59-5, 10534-59-5 Tetrabutylammonium acetate 82707, acatalyst-ligand compound, is more and more widely used in various.
Reference£º
Patent; AVECIA PHARMACEUTICALS LIMITED; WO2005/92867; (2005); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI